Caplin Point Laboratories reported a solid performance for the quarter ending December 31, 2024, with key financial indicators showing significant growth.
- Revenue from Operations: ₹492.96 crore, a YoY increase from ₹435.50 crore in Q3 FY24.
- Total Income: ₹524.32 crore, up from ₹452.68 crore in the same quarter last year.
- Net Profit: ₹140.07 crore, reflecting a YoY growth of 17% from ₹119.82 crore in Q3 FY24.
- Profit Before Tax (PBT): ₹177.26 crore, compared to ₹145.41 crore in the previous year’s quarter.
- Total Expenses: ₹347.05 crore, rising from ₹307.29 crore YoY due to higher material and employee costs.
- Revenue Growth YoY: ≈ 13.2%
- Profit After Tax YoY: ≈ 16.9%
- Profit Before Tax YoY: ≈ 21.9%
The company attributed the robust growth to higher operational efficiencies and a strong demand environment. Its continuous focus on cost optimization and product diversification has further strengthened margins.
With steady demand and consistent expansion into new markets, Caplin Point remains well-positioned for sustained growth in the pharmaceutical space.